Global Anemia Drugs Market 2016-2021: Market to Grow at a CAGR of 9.05% on Account of Rising Incidences of Anemia

Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Global Anemia Drugs Market (Iron Deficiency, Sickle Cell, CKD, Aplastic Anemia): Analysis By Region, By Country (2016-2021)" report to their offering.

Global Anemia Drugs Market is forecasted to grow at a CAGR of 9.05% during 2016-2021F, on account of rising incidences of anemia globally.

Rising development of pipeline drugs combined with the growing awareness of disease in developing countries has resulted in the growth of Anemia Drugs market. Anemia Drugs has been majorly caused due to the lack of iron intake and less iron absorption mainly among pregnant women, women of reproductive age and young children.

Among the various types of anemia, market is expected to be driven by CKD anemia, due to the growing research and development towards new biosimilars such as Hypoxia-inducible factors. However, launch of late pipeline drugs such as Rivipansel and Vepoloxamer for sickle cell anemia treatment are anticipated to drive the market in forecast period.

While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Global Anemia Drugs Market: An Overview

5. North America Anemia Drugs Market: An Analysis

6. Europe Anemia Drugs Market: An Analysis

7. APAC Anemia Drugs Market: An Analysis

8. Latin America Anemia Drugs Market: An Analysis

9. MEA Anemia Drugs Market: An Analysis

10. Market Dynamics

11. M&A and Licensing Route to the Anemia Drugs Treatment Market

12. SWOT Analysis

13. Porter Five Force Model

14. Company Profiling and Drug Market Potential

- Acceleron Pharma
- Akebia therapeutics
- Bayer AG
- Bluebird bio
- Celgene Corporation
- Eli Lilly
- Fibrogen
- GlaxoSmithKline
- Global Blood Therapeutics (GBT)
- GlycoMimetics
- Mast Therapeutics
- Onconova Therapeutics
- Pieris Pharmaceuticals
- Regen biopharma

For more information about this report visit http://www.researchandmarkets.com/research/7hf3md/global_anemia

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Hematological Drugs